RxDoctor Payments Data

Jessica Quesenberry, APRN

Family · Dayton, OHNPI 1063769826

Payments from drug & device makers

$3,024in general payments, 2019–2025

Across 163 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$596
  • AstraZeneca$506
  • Boehringer Ingelheim$251
  • Sanofi$217
  • Regeneron Healthcare Solutions, Inc.$180
  • Takeda Pharmaceuticals U.S.A., Inc.$131
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,00699%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,024 in reported general payments places this provider in the 85th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$39,051
Medicare patients
309
Services billed
480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter85$55,082
Breztri AerosphereBudesonide/Glycopyr/Formoterol34$21,826
Stiolto RespimatTiotropium Br/Olodaterol Hcl29$18,244
Spiriva RespimatTiotropium Bromide21$12,652
Breo ElliptaFluticasone/Vilanterol21$12,432
SymbicortBudesonide/Formoterol Fumarate11$2,467
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,532
Albuterol Sulfate HfaAlbuterol Sulfate75$1,291
Roflumilast15$619
Ventolin HfaAlbuterol Sulfate11$607
Prednisone211$493
Doxycycline Hyclate68$439
Azelastine Hcl33$362
Fluticasone Propionate40$320
Azithromycin72$192

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$596$67,514106 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$251$30,89650 claims
AstraZenecaBreztri Aerosphere, Symbicort$506$24,29345 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,812 family providers in Ohio.

Other family in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →